Tweet
vTv Therapeutics Inc (NASDAQ:VTVT) major shareholder Ronald O. Perelman purchased 570,777 shares of the company's stock in a transaction that occurred on Friday, August 10th. The shares were acquired at an average price of $4.38 per share, for a total transaction of $2,500,003.26. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link . Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Shares of VTVT stock opened at $1.10 on Friday. The company has a market cap of $43.51 million, a P/E ratio of -0.66 and a beta of 1.67. The company has a debt-to-equity ratio of -0.15, a quick ratio of 0.19 and a current ratio of 0.19. vTv Therapeutics Inc has a 12 month low of $0.65 and a 12 month high of $8.40. Get vTv Therapeutics alerts:
vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings results on Friday, August 3rd. The biotechnology company reported ($0.29) EPS for the quarter, missing the Zacks' consensus estimate of ($0.25) by ($0.04). The company had revenue of $2.47 million for the quarter, compared to the consensus estimate of $2.46 million. research analysts forecast that vTv Therapeutics Inc will post -0.87 EPS for the current year.
A number of brokerages recently commented on VTVT. Zacks Investment Research upgraded shares of vTv Therapeutics from a "hold" rating to a "buy" rating and set a $1.75 price target on the stock in a research note on Thursday, May 24th. ValuEngine upgraded shares of vTv Therapeutics from a "sell" rating to a "hold" rating in a research note on Wednesday, May 2nd. Seven investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of "Hold" and a consensus price target of $13.11.
Several hedge funds have recently made changes to their positions in VTVT. Millennium Management LLC purchased a new stake in shares of vTv Therapeutics during the 4th quarter valued at approximately $377,000. C WorldWide Group Holding A S bought a new stake in vTv Therapeutics during the 1st quarter worth approximately $399,000. Finally, JPMorgan Chase & Co. increased its holdings in vTv Therapeutics by 55.9% during the 1st quarter. JPMorgan Chase & Co. now owns 327,728 shares of the biotechnology company's stock worth $1,333,000 after acquiring an additional 117,513 shares during the period. Institutional investors own 13.42% of the company's stock.
About vTv Therapeutics
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease